drugset / Trial / NCT01489618

"Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency

NCT01489618 ↗

RandomizedParallel-groupOpen-labelPrevention

Summary

The main objective of this study is to evaluate and to compare the specific antibody response to a " prime-boost " vaccine strategy combining the seven valence pneumococcal conjugate vaccine (PnCj) prime at W0 followed by the administration of the pneumococcal capsular polysaccharide vaccine (PPS) boost at W4, to the administration of the pneumococcal capsular polysaccharide vaccine (PPS) alone at W4 in patients with common variable immunodeficiency.

Timeline

Start
2009-06
Primary completion
2013-03
Completion
2013-03

Outcome

Outcome not reported

Stopped: “End of production”

Drugs

EvaluationDrugModalityDoseRoute
Comparator PPS Vaccine — —
Subject PnCJ Vaccine — —